Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Double Dummy, Multicenter Phase II/III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated with Chemotherapy

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Double Dummy, Multicenter Phase II/III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated with Chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icotinib (Primary) ; Gefitinib
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ICOGEN
  • Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma

    • Most Recent Events

    • 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
    • 02 Jun 2017 Results (n=352) of updated analysis evaluating the ability of blood based proteomic test to predict outcomes in Icotinib treated patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results (n=357) of retrospective analysis demonstrating the utility of VeriStrat in a Chinese cohort treated with EGFR TKI presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top